Literature DB >> 30124405

From Culturomics to Clinical Microbiology and Forward.

Grégory Dubourg, Sophie Baron, Frédéric Cadoret, Carine Couderc, Pierre-Edouard Fournier, Jean-Christophe Lagier, Didier Raoult.   

Abstract

Culturomics has permitted discovery of hundreds of new bacterial species isolated from the human microbiome. Profiles generated by using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry have been added to the mass spectrometer database used in clinical microbiology laboratories. We retrospectively collected raw data from MALDI-TOF mass spectrometry used routinely in our laboratory in Marseille, France, during January 2012-March 2018 and analyzed 16S rDNA sequencing results from misidentified strains. During the study period, 744 species were identified from clinical specimens, of which 21 were species first isolated from culturomics. This collection involved 105 clinical specimens, accounting for 98 patients. In 64 cases, isolation of the bacteria was considered clinically relevant. MALDI-TOF mass spectrometry was able to identify the species in 95.2% of the 105 specimens. While contributing to the extension of the bacterial repertoire associated with humans, culturomics studies also enlarge the spectrum of prokaryotes involved in infectious diseases.

Entities:  

Keywords:  MALDI-TOF MS; bacteria; clinical microbiology; culture; culturomics; matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; microbiology; new species

Mesh:

Substances:

Year:  2018        PMID: 30124405      PMCID: PMC6106433          DOI: 10.3201/eid2409.170995

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


The diagnosis of bacterial diseases in clinical microbiology has relied on phenotypic identification, based on the bacterial repertoire known to be associated with humans. This mode of identification, which is, in fact, recognition of previously described microorganisms, does not allow for the identification of new bacteria. Recently, the systematic use of universal 16S rDNA gene sequencing of cultivated bacteria that presented an atypical phenotypical profile paved the way for identifying rare, fastidious, and new microorganisms (,). However, this method implies redefining specific phenotypical characteristics, which sometimes cannot be done because of the limited number of available biochemical tests. More recently, the revolution provided by matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry identification permits comparison of a protein spectrum obtained from a colony with a database, which can be permanently incremented with newly identified bacteria (,). The use of a cutoff identification score, with values in the range of 1.7–2, enables correct identification of the isolate. However, when MALDI-TOF mass spectrometry recognizes bacteria never previously associated with humans, it is reasonable to carry out confirmation by sequencing the 16S rDNA gene. The main advantage of MALDI-TOF mass spectrometry compared with sequencing methods is that it is extremely fast and cost-effective (,). Indeed, the cost involves mainly the cost of the machine; the individual cost per test is insignificant. Thus, the ease in testing bacterial colonies led us to establish the repertoire of commensal bacteria of the human microbiota in the laboratory at IHU Méditerranée Infection in Marseille, France, by using a high-throughput culture and MALDI-TOF mass spectrometry identification. Sequencing of the 16S rDNA gene enables identification of atypical bacteria with definition of new bacterial species, whose genomes are then sequenced. This approach, called culturomics (,), has made possible the addition of 672 bacteria to the known repertoire of the bacteria already isolated from the human mucosa. Other teams, in parallel, have used similar approaches (,). The usefulness of culturomics in increasing knowledge of the repertoire of cultivable bacteria from human mucous membranes appears clear for microbiota studies. However, the benefit of this process in clinical microbiology is prone to controversy. We speculated that commensal bacteria found in humans may be involved in opportunistic infections. In our experience, the creation of new spectra enabled us to increment our MALDI-TOF mass spectrometry database used for clinical microbiology, thus enabling recognition of bacterial species first isolated as a part of culturomics studies and improving the accuracy of diagnosis of infectious diseases involving bacteria.

Materials and Methods

Settings

All data included in this study were obtained from the routine microbiology laboratory at IHU Méditerranée Infection, which receives a mean annual number of 350,400 samples from the 4 Marseille university hospitals (Timone, Conception, North, and Sainte-Marguerite hospitals), which contain a total of 3,700 beds. Retrospective data were collected for January 2012–March 2018.

Routine Bacteriological Practices

We analyzed samples according to standard microbiological procedures, as previously described, depending on the specimen (–). This process included systematic inoculation onto Columbia agar with 5% sheep blood (BioMérieux, Craponne, France), chocolate agar (BioMérieux) (excluding urine and fecal samples), and specific media such as colistin-nalidixic agar or MacConkey agar (both BioMérieux) for specimens potentially contaminated by resident flora. Blood cultures were incubated into a Bactec device (Becton Dickinson, Le Pont de Claix, France) and analyzed as previously described ().

Specific Cultures

We plated fecal specimens taken following a regional outbreak of Clostridioides (formerly Clostridium) difficile 027 during May 2013–March 2018 (), in which toxin detection was positive using GeneXpert C. difficile PCR (Cepheid, Paris, France) after ethanol treatment (), to obtain C. difficile isolates. We also investigated possible multidrug-resistant bacteria carriage by plating on chromID MRSA agar for methicillin-resistant Staphylococcus aureus, chromID CARBA SMART medium (BioMérieux) for carbapenemase-producing Enterobacteriaceae (CPE), and Drigalski/MacConkey agar (BioMérieux) for third-generation, cephalosporin-resistant, gram-negative bacteria.

Identification of Colonies

We performed bacterial identification on colonies using MALDI-TOF mass spectrometry, as previously described (,). We considered identification to be correct when the identification score was >1.9 and when the same single species was recognized. When identification did not meet these criteria, we performed proteic extraction using formic acid and acetonitrile (). If identification was still incorrect following the proteic extraction protocol, we performed 16S rDNA sequencing systematically, as previously described (), in 3 situations: when the identification score was <1.9 despite proteic extraction, when multiple different species were recognized with a correct identification score, and when a bacterium was isolated for the first time in the clinical microbiology laboratory.

Culturomics Studies

In brief, culturomics consists of the multiplication of culture conditions applied to human specimens to increase the repertoire of the human microbiome. The pioneering study used 212 conditions (); this number was reduced to 70 in 2012 (,) and then to 18 in 2014 (). In addition, several specific conditions were designed for archaea, microcolonies, proteobacteria, and microaerophilic and halophilic bacteria. Most specimens used were fecal samples. However, respiratory, vaginal, and urine samples have been analyzed recently in the context of culturomics studies. Identification has also been performed using MALDI-TOF mass spectrometry. Colonies were considered correctly identified when 2 colonies exhibited an identification score >1.9. If identification scores were not correct after 3 attempts, sequencing of the 16S rDNA gene was performed (). If there was <98.7% similarity with the closest neighbor, the bacterial isolate was considered to be a new species ().

Updating the MALDI-TOF Mass Spectrometry Database

The database used for routine bacterial identification is updated through 3 sources: updates from the MALDI-TOF mass spectrometry manufacturer, updates from culturomics studies, and routine laboratory results. Updates from culturomics studies and routine laboratory results are based on 16S rDNA sequencing results.

Analysis of Data from MALDI-TOF Mass Spectrometry Used in the Clinical Microbiology Laboratory

We retrospectively collected raw data from MALDI-TOF mass spectrometry used in the microbiology laboratory involving identifications performed during January 2012–March 2018, which are saved monthly. Data were deduced from the samples. These data do not consider the clinical relevance of the identified microorganism, the final result, or multiple attempts to identify the colony using MALDI-TOF mass spectrometry.

Results

Bacterial Identification in Clinical Microbiology Laboratory

During January 2012–March 2018, the clinical microbiology laboratory performed 351,937 nondereplicated bacterial identifications using MALDI-TOF mass spectrometry. Of these, 28,391 (8.1%) were unidentified or misidentified. When we looked at the yearly ratio of unidentified bacteria, we noticed that it fell from 17.7% in 2012 to 3.6% in 2018 (Figure). Overall, we identified 744 unique bacterial species correctly using MALDI-TOF mass spectrometry.
Figure

Annual ratio of unidentified bacteria and evolution of the number of spectral references available in the matrix-assisted laser desorption/ionization time-of-flight mass spectrometry database in a clinical laboratory in Marseille, France.

Annual ratio of unidentified bacteria and evolution of the number of spectral references available in the matrix-assisted laser desorption/ionization time-of-flight mass spectrometry database in a clinical laboratory in Marseille, France.

Contribution to MALDI-TOF Mass Spectrometry Database Updates

During the study period, we added 4,539 references to our database. Updates from the manufacturer comprised 3,255 references, whereas 983 references came from routine laboratory results. In addition, 306 (23.4%) updates were from new bacterial species discovered as a part of culturomics studies. Overall, references from the manufacturer represented 87% of the total database, routine laboratory results represented 8%, and new culturomics species represented 5% (Figure).

Routine Identification of Species Isolated as Part of Culturomics Studies

Among the 351,937 bacterial identifications performed routinely during the study period, we identified species first isolated from culturomics studies in 105 clinical specimens, accounting for 98 patients. This collection represents a total of 21 species, accounting for 2.8% (21/744) of the overall microbiology laboratory bacterial diversity (Table 1).
Table 1

Main features of the bacteria discovered as part of culturomics studies identified in a clinical microbiology laboratory*

SpeciesCulturomics studyCSUR no.StrainGenBank accession no.Date of spectrum implementationNo. casesReferences
Actinomyces bouchesdurhonensis Gut microbiota (storied samples)P2825Marseille-P2825TLT5763852017 Apr3Unpub. data
Actinomyces ihuae Gut microbiota (HIV)P2006SD1LN8669972015 Jul17(6,20)
Actinomyces marseillensis Respiratory microbiotaP2818Marseille-P2818TLT576400Not added1(21)
Alistipes jeddahensis Gut microbiotaP1209AL1LK0211162015 Oct4(6,22)
Anaerosalibacter massiliensis Gut microbiota (Polynesia)P762ND1HG3156732013 Apr1(6,23)
Bacteroides timonensis Gut microbiota (anorexia nervosa)P194AP1JX0416392016 Apr2(6,24)
Butyricimonas phocaeensis Gut microbiota (obese)P2478AT9LN8815972015 Nov1(6,25)
Clostridium culturomicsense Gut microbiota (Saudian obese)P1184CL6LK0211172014 Sep1(6,26)
Clostridium jeddahtimonense Gut microbiota (obese)P1230CL2LK0211182014 Aug7(6)
Clostridium massilioamazoniense Gut microbiota (Polynesia)P1360ND2HG3156722013 May1(6)
Clostridium saudii Gut microbiota (Saudian obese)P697JCCHG7260392014 Aug11(6,27)
Corynebacterium ihuae Gut microbiota (antimicrobials)P892GD6JX4247682013 May3(6,28)
Corynebacterium lascolaense Urinary microbiotaP2174MC3LN8816122013 Sep6(6)
Corynebacterium phoceense Urinary microbiotaP1905MC1LN8497772015 May12(6,29)
Gabonia massiliensis Gut microbiotaP1910GM3LN8497892017 Apr1(6,30)
Nosocomicoccus massiliensis Gut microbiota (HIV)P246NP2JX4247712012 Feb1(6,31)
Peptoniphilus grossensis Gut microbiota (obese)P184ph5JN8374912015 Nov18(6,32)
Polynesia massiliensis Gut microbiota (Polynesia)P1280MS3HF9529202013 Mar1(6)
Prevotella ihuae Gut microbiota (fresh feces)P3385Marseille-P3385TLT631517Not added1(33)
Pseudomonas massiliensis Gut microbiota (Polynesia)P1334CB1LK9853962015 Apr5(6,34)
Varibaculum timonense Gut microbiota (fresh feces)P3369Marseille-P3369TLT797538Not added1(33)

*Accession numbers indicate nucleotide sequences. CSUR, Collection de Souches de l’Unité des Rickettsies (an international strain collection).

*Accession numbers indicate nucleotide sequences. CSUR, Collection de Souches de l’Unité des Rickettsies (an international strain collection). Among the 105 colonies identified as new species isolated as a part of culturomics studies, identification was correct for 100 (95.2%) using MALDI-TOF mass spectrometry. Thus, 16S rDNA gene sequencing was required for 5 strains to achieve final identification. MALDI-TOF mass spectrometry was not able to provide a reliable identification for Varibaculum timonense, Prevotella ihuae, Actinomyces ihuae, and 2 Corynebacterium phoceense isolates. We confirmed identification of 9 supplementary strains, representing 5 species (Corynebacterium lascolaense, Actinomyces ihuae, Corynebacterium ihuae, Nosocomiicoccus massiliensis, and Pseudomonas massiliensis), using 16S rDNA gene sequencing (Tables 2,3). Overall, we sequenced 14 isolates, accounting for 8 species, for the 16S rDNA gene.
Table 2

Identification of bacterial pathogens by MALDI-TOF mass spectrometry, Marseille, France*

SpeciesMALDI-TOF identification (score)SpecimenDuplicates per patient?†
Actinomyces bouchesdurhonensis Actinomyces bouchesdurhonensis (1.85)Pharynx swabNo
A. bouchesdurhonensis A. bouchesdurhonensis (1.9)AbscessNo
Actinomyces ihuae Actinomyces ihuae (1.97)AbscessNo
A. ihuae A. ihuae (1.9)AbscessNo
A. ihuae A. ihuae (2.5)AbscessNo
A. ihuae A. ihuae (1.92)AbscessNo
A. ihuae A. ihuae (2.5)AbscessNo
A. ihuae A. ihuae (1.73)AbscessNo
A. ihuae A. ihuae (2.23)AbscessNo
A. ihuae A. ihuae (2.2)AbscessNo
A. ihuae A. ihuae (2.1)AbscessNo
A. ihuae A. ihuae (2.1)BoneNo
A. ihuae A. ihuae (2.52)Puncture fluidNo
A. ihuaeA. ihuae (2.47)Puncture fluidNo
A. ihuaeActinomyces spp. (1.65)BiopsyNo
A. ihuaeA. ihuae (2.32)AbscessNo
A. ihuaeA. ihuae (2.33)AbscessNo
A. ihuaeA. ihuae (1.95)Puncture fluidNo
A. ihuaeA. ihuae (2.07)AbscessNo
Actinomyces marseillensis Actinomyces marseillensis (NA)Blood cultureNo
Alistipes jeddahensis Alistipes jeddahensis (1.97)AbscessNo
Bacteroides timonensis Bacteroides timonensis (1.95)Blood cultureYes
B. timonensis B. timonensis (1.88)Blood cultureYes
B. timonensis B. timonensis (1.96)Blood cultureNo
Corynebacterium ihuaeCorynebacterium ihuae (2)Blood cultureNo
C. ihuae C. ihuae (2.2)WoundNo
C. ihuae C. ihuae (1.8)Blood cultureNo
Corynebacterium lascolaense Corynebacterium lascolaense (2.2)UrineNo
C. lascolaense C. lascolaense (2.3)PacemakerNo
C. lascolaense C. lascolaense (2.1)UrineYes
C. lascolaense C. lascolaense (2.14)UrineYes
C. lascolaenseC. lascolaensis (2.2)UrineNo
Corynebacterium phoceense Corynebacterium phoceense (1.91)UrineNo
C. phoceense Corynebacterium spp. (2.3)UnknownNo
C. phoceense C. phoceense (2.6)Blood cultureNo
C. phoceenseNo reliable identificationBlood cultureNo
Nosocomicoccus massiliensisNosocomicoccus massiliensis (2.3)Blood cultureNo
Peptinophilus grossensis Peptinophilus grossensis (2.1)AbscessNo
P. grossensis P. grossensis (2.18)BiopsyNo
P. grossensis P. grossensis (1.9)AbscessNo
P. grossensis P. grossensis (2.3)BiopsyNo
P. grossensis P. grossensis (1.9)BiopsyYes
P. grossensis P. grossensis (2.2)BiopsyYes
P. grossensis P. grossensis (2.18)BiopsyNo
P. grossensis P. grossensis (2)MaterialNo
P. grossensis P. grossensis (1.78)AbscessNo
P. grossensis P. grossensis (2.1)AbscessNo
P. grossensis P. grossensis (2.15)AbscessNo
P. grossensis P. grossensis (1.9)Puncture fluidNo
P. grossensis P. grossensis (2.1)Puncture fluidYes
P. grossensis P. grossensis (2.3)Puncture fluidYes
P. grossensis P. grossensis (2.2)Puncture fluidNo
P. grossensis P. grossensis (2.1)AbscessYes
P. grossensis P. grossensis (2.1)AbscessYes
P. grossensis P. grossensis (1.9)Puncture fluidNo
P. grossensis P. grossensis (2.3)BiopsyNo
P. grossensis P. grossensis (2.31)BiopsyNo
P. grossensis P. grossensis (1.86)AbscessNo
Polynesia massiliensis Polynesia massiliensis (2.21)Peritoneal fluidNo
Prevotella ihuae No reliable identificationAbscessNo
Pseudomonas massiliensis Pseudomonas massiliensis (2.5)Blood cultureNo
Pseudomonas massiliensis Pseudomonas massiliensis (2)Blood cultureNo
Pseudomonas massiliensisPseudomonas massiliensis (1.9)Blood cultureNo
Varibaculum timonense
No reliable identification
Abscess
No
*MALDI-TOF, matrix-assisted laser desorption/ionization time-of-flight; NA, not available.
†Replicated isolates in different specimens from the same patient.
‡Strains for which 16S rDNA sequencing was performed.
Table 3

Identification of bacteria discovered as a part of culturomics studies in the clinical microbiology laboratory as commensals, Marseille, France*

SpeciesMALDI-TOF mass spectrometry identification (score)SpecimenDuplicates per patient?†Additional information
Actinomyces bouchesdurhonensis A. bouchesdurhonensis (2)Larynx biopsyNoPolymicrobial
Alistipes jeddahensis Alistipes jeddahensis (2.38)Liquid fecesNoSeeking Salmonella spp.
A. jeddahensis A. jeddahensis (2.45)Liquid fecesNoSeeking Salmonella spp.
A. jeddahensis A. jeddahensis (2.5)Liquid fecesNoSeeking Salmonella spp.
Anaerosalibacter massiliensis Anaerosalibacter massiliensis (1.78)Rectal swabNoSeeking MDR bacteria
Butyricimonas phocaeensis Butyricimonas phoaceensis (2.36)Liquid fecesNoSeeking toxigenic CD
Clostridium culturomicsense Clostridium culturomicsense (2)Liquid fecesNoSeeking toxigenic CD
Clostridium jeddahtimonense Clostridium jeddahtimonense (2.1)Liquid fecesNoSeeking toxigenic CD
C. jeddahtimonense C. jeddahtimonense (2.3)Liquid fecesNoSeeking toxigenic CD
C. jeddahtimonense C. jeddahtimonense (2.4)Liquid fecesNoSeeking toxigenic CD
C. jeddahtimonense C. jeddahtimonense (2.1)Liquid fecesNoSeeking toxigenic CD
C. jeddahtimonense C. jeddahtimonense (2.2)Liquid fecesYesSeeking toxigenic CD
C. jeddahtimonense C. jeddahtimonense (1.72)Liquid fecesYesSeeking toxigenic CD
C. jeddahtimonense C. jeddahtimonense (2.3)Liquid fecesNoSeeking toxigenic CD
C. jeddahtimonense C. jeddahtimonense (2.1)Liquid fecesNoSeeking toxigenic CD
Clostridium massilioamazoniense Clostridium massilioamazoniense (1.7)Liquid fecesNoSeeking toxigenic CD
Clostridium saudii Clostridium saudii (2.5)Liquid fecesNoSeeking toxigenic CD
C. saudii C. saudii (1.74)Liquid fecesNoSeeking toxigenic CD
C. saudii C. saudii (2.5)Liquid fecesNoSeeking toxigenic CD
C. saudii C. saudii (1.94)Liquid fecesNoSeeking toxigenic CD
C. saudii C. saudii (2.18)Liquid fecesNoSeeking toxigenic CD
C. saudii C. saudii (1.77)Liquid fecesNoSeeking toxigenic CD
C. saudii C. saudii (1.93)Liquid fecesNoSeeking toxigenic CD
C. saudii C. saudii (2.1)Liquid fecesNoSeeking toxigenic CD
C. saudii C. saudii (1.9)Liquid fecesNoSeeking toxigenic CD
C. saudii C. saudii (2.47)Liquid fecesNoSeeking toxigenic CD
C. saudii C. saudii (1.83)Liquid fecesNoSeeking toxigenic CD
Corynebacterium lascolaense Corynebacterium lascolaense (1.85)Intrauterine deviceNoNot considered
C. lascolaense C. lascolaense (2.1)UrineNoGrowth not significant
Corynebacterium phoceense Corynebacterium phoceense (2.1)VaginaNoNot considered
C. phoceense C. phoceense (1.9)VaginaNoNot considered
C. phoceense C. phoceense (2.1)VaginaNoNot considered
C. phoceense C. phoceense (2)VaginaNoNot considered
C. phoceense C. phoceense (2.2)VaginaNoNot considered
C. phoceense C. phoceense (2)VaginaNoPolymicrobial
C. phoceense C. phoceense (2.2)VaginaNoNot considered
C. phoceense C. phoceense (1.97)UrineNoPolymicrobial
Gabonia massiliensis Gabonia massiliensis (2.3)Liquid fecesNoSeeking MDR bacteria
Pseudomonas massiliensis Pseudomonas massiliensis (2)Skin swabYesSeeking S. aureus carriage
P. massiliensis
P. massiliensis (2.5)
Skin swab
Yes
Seeking S. aureus carriage
*MALDI-TOF, matrix-assisted laser desorption/ionization time-of-flight.
†Replicated isolates in different specimens from the same patient.

Species Potentially Relevant as Human Pathogens

Among the 105 isolates included in this work, 64 were isolated as potential pathogens, accounting for 14 different species. Most were anaerobes that were cultured from abscesses or punctures, often involved in cases of polymicrobial infections. Peptoniphilus grossensis (18 cases) and Actinomyces ihuae (17 cases) were the most commonly isolated bacteria (Table 1). These species were initially cultured from the human gut. Special attention was given to A. ihuae infections (Table 4), which were strongly associated with breast abscess or genital area infections. Also, 10 bacteremia-involved species were isolated as a part of culturomics studies. Bacteroides timonensis was thus isolated in 3 blood cultures from 2 patients, whereas Pseudomonas massiliensis was found in 3 bacteremia episodes. Corynebacterium phoceense and Corynebacterium ihuae were recovered from 2 bloodstream infection episodes, whereas Actinomyces marseillensis and Nosocomicoccus massiliensis were each isolated from 1 blood sample (from 2 different patients). B. timonensis, P. massiliensis, N. massiliensis, and C. ihuae were first cultured from the human gut, whereas A. marseillensis was first isolated from respiratory microbiota and C. phoceense was first isolated from urinary microbiota. Overall, species cultured as part of culturomics studies were found to be potential pathogens in 59 different patients (Table 2). The significance of the presence of P. massiliensis in a lens from a patient with keratitis was ultimately not interpreted.
Table 4

Characteristics of 17 persons with A. ihuae infection, Marseille, France, April 2015–March 2018*

Patient no.Patient age, y/sexSampling siteIncubation time, hCulture resultMALDI-TOF mass spectrometry score16S rRNA result
124/FPeriareolar right breast48 Polymicrobial2.54NA
226/FUmbilical collection48 Pure2.5NA
337/MPeriareolar left breast72 Polymicrobial1.97NA
433/FBreast72 Polymicrobial2.1NA
577/FBone72 Polymicrobial2.1NA
622/MTesticular collection96 Pure1.95A. ihuae 99.70%
756/MBack48 Pure2.32A. ihuae 99.70%
855/FLabia majora72 Polymicrobial2.07A. ihuae 99.70%
930/FLabia majora72 Pure2.47A. ihuae 99.70%
1026/FLabia majora72 Polymicrobial2.33A. ihuae 99.60%
1144/MLeg ulcer48 PolymicrobialNAA. ihuae 99.50%
1266/MCervical collection72 Polymicrobial2.23NA
1349/MSuperinfected sebaceous cyst48 Polymicrobial1.9NA
1418/FSacrococcygeal cyst96 Pure2.45NA
1526/FLabia majora72 Polymicrobial2.2NA
1645/FBreast abcess72 Polymicrobial1.73NA
1744/MAxillar abcess96 Polymicrobial1.92NA
* MALDI-TOF, matrix-assisted laser desorption/ionization time-of-flight; NA, not available

Species Isolated as Human Commensal Members

In this work, 40 isolates corresponding to 12 species discovered as a part of culturomics studies were isolated as belonging to the human flora. Of these, 22 were recovered when evaluating for toxigenic C. difficile, following a positive result with the GeneXpert C. difficile test. C. saudii was isolated in this context 11 times, followed by C. jeddahtimonense (8 times), C. culturomicsense, Butyricimonas phocaeensis, and Anaerosalibacter massiliensis (1 time each) (Table 3). These 5 species were first cultured from fecal specimens (Table 1). In addition, Corynebacterium lascolaense was identified in 1 urine specimen, but in an insufficient quantity to be considered clinically relevant. Similarly, C. phoceense was recovered from 1 urine sample and from 7 vaginal swabs but was never reported to a physician in this context. These species were first cultured from urinary microbiota. Finally, Pseudomonas massiliensis, which was cultured from the human gut, was also recovered twice from skin swabs collected from the same physician after an epidemiologic investigation. Overall, species cultured for the first time as a part of culturomics studies were found as commensals in 38 different patients.

Discussion

This work constitutes the proof of concept that exploration of the repertoire of commensal bacteria enables identification of microorganisms involved in clinical microbiology. Indeed, the strategy of combining high-throughput culture techniques, MALDI-TOF mass spectrometry identification, and 16S rDNA gene sequencing of misidentified isolates enabled us to add 306 spectral references for 292 different new bacterial species to our laboratory’s database. Thus, with culturomics, 21 new species were identified 105 times, in 98 patients. The results are robust; identification scores were all >1.9 with exclusion of multiple identifications. In addition, identification of 9 strains using 16S rDNA sequencing, accounting for 5 species, confirmed the initial recognition by MALDI-TOF mass spectrometry (Table 2). These results strengthen our belief that identifying commensal microbes provides a valuable contribution to clinical microbiology, as revealed by the decrease in the number of unidentified colonies by MALDI-TOF mass spectrometry over time (Figure). As exemplified for A. ihuae infections (Table 4), these microorganisms, which were isolated mainly from the human gut, can probably be found frequently in polymicrobial cultures. Thus, the microbiologist may be tempted to abandon the final identification of a microorganism found in such a situation, concluding that the infection is polymicrobial. The extension of the bacterial repertoire associated with humans will considerably increase the number of bacteria associated with human diseases. In this study alone, over a 5-year period, 2.8% (21/744) of the overall identified bacteria would not have been identified without incrementing the MALDI-TOF mass spectrometry database with spectra obtained from culturomics studies. On the whole, pathogenic microbes are also often found as commensals, as is currently well known for C. difficile, S. aureus, and S. pneumoniae (–). In our study, for example, Corynebacterium phoceense, Pseudomonas massiliensis, and C. lascolaense were found as both commensals and pathogens. This finding highlights the need for establishment of a repertoire of human microbes (), which was recently estimated at 2,776 species, of which more than 10% were recovered by culturomics studies. Such a repertoire of prokaryotes associated with humans not only benefits microbiota studies, through notation of unknown sequences with new species genome sequencing, but also enables studying the role of these species in human infections (). We estimate that, among the cases included here, the presence of species cultured as part of culturomics studies was potentially clinically relevant for 60 of them (61.2%). The online availability of the MALDI-TOF mass spectrometry spectra obtained from these species discovered by culturomics (http://www.mediterranee-infection.com/article.php?laref=256&titre=urms-database) ensures their further identification by other laboratories. Culturomics was initially designed to exhaustively identify commensals inhabiting human surfaces and thus can potentially lead in the future to personal medical interventions as a part of microbiome studies. However, the thinnest barrier between commensalism and pathogenicity, which should lead researchers to rethink Koch’s postulate (), has rendered culturomics studies useful in the field of clinical microbiology despite a potential skepticism. We show herein that, while contributing to the extension of the bacterial repertoire associated with humans, culturomics studies also enlarge the spectrum of prokaryotes involved in infectious diseases.
  40 in total

1.  Culturomics identified 11 new bacterial species from a single anorexia nervosa stool sample.

Authors:  A Pfleiderer; J-C Lagier; F Armougom; C Robert; B Vialettes; D Raoult
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-06-02       Impact factor: 3.267

2.  Ongoing revolution in bacteriology: routine identification of bacteria by matrix-assisted laser desorption ionization time-of-flight mass spectrometry.

Authors:  Piseth Seng; Michel Drancourt; Frédérique Gouriet; Bernard La Scola; Pierre-Edouard Fournier; Jean Marc Rolain; Didier Raoult
Journal:  Clin Infect Dis       Date:  2009-08-15       Impact factor: 9.079

3.  Insight into alteration of gut microbiota in Clostridium difficile infection and asymptomatic C. difficile colonization.

Authors:  Lihua Zhang; Danfeng Dong; Cen Jiang; Zhen Li; Xuefeng Wang; Yibing Peng
Journal:  Anaerobe       Date:  2015-03-26       Impact factor: 3.331

4.  Complementarity between targeted real-time specific PCR and conventional broad-range 16S rDNA PCR in the syndrome-driven diagnosis of infectious diseases.

Authors:  A-S Morel; G Dubourg; E Prudent; S Edouard; F Gouriet; J-P Casalta; F Fenollar; P E Fournier; M Drancourt; D Raoult
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-10-28       Impact factor: 3.267

5.  Microbial Culturomics Application for Global Health: Noncontiguous Finished Genome Sequence and Description of Pseudomonas massiliensis Strain CB-1T sp. nov. in Brazil.

Authors:  Lucie Bardet; Teresa Cimmino; Clémence Buffet; Caroline Michelle; Jaishriram Rathored; Fatalmoudou Tandina; Jean-Christophe Lagier; Saber Khelaifia; Jônatas Abrahão; Didier Raoult; Jean-Marc Rolain
Journal:  OMICS       Date:  2017-06-26

6.  Lactobacillus rhamnosus bacteremia: an emerging clinical entity.

Authors:  F Gouriet; M Million; M Henri; P-E Fournier; D Raoult
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-04-28       Impact factor: 3.267

Review 7.  Culturing the human microbiota and culturomics.

Authors:  Jean-Christophe Lagier; Grégory Dubourg; Matthieu Million; Frédéric Cadoret; Melhem Bilen; Florence Fenollar; Anthony Levasseur; Jean-Marc Rolain; Pierre-Edouard Fournier; Didier Raoult
Journal:  Nat Rev Microbiol       Date:  2018-05-01       Impact factor: 60.633

8.  Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry identification of mycobacteria in routine clinical practice.

Authors:  Amel El Khéchine; Carine Couderc; Christophe Flaudrops; Didier Raoult; Michel Drancourt
Journal:  PLoS One       Date:  2011-09-13       Impact factor: 3.240

9.  Non contiguous-finished genome sequence and description of Peptoniphilus grossensis sp. nov.

Authors:  Ajay Kumar Mishra; Perrine Hugon; Catherine Robert; Didier Raoult; Pierre-Edouard Fournier
Journal:  Stand Genomic Sci       Date:  2012-12-19

10.  Actinomyces gerencseriae hip prosthesis infection: a case report.

Authors:  Grégory Dubourg; Marion Delord; Frédérique Gouriet; Pierre-Edouard Fournier; Michel Drancourt
Journal:  J Med Case Rep       Date:  2015-09-28
View more
  8 in total

Review 1.  Human Bacterial Repertoire of the Urinary Tract: a Potential Paradigm Shift.

Authors:  Aurélie Morand; Florent Cornu; Jean-Charles Dufour; Michel Tsimaratos; Jean-Christophe Lagier; Didier Raoult
Journal:  J Clin Microbiol       Date:  2019-02-27       Impact factor: 5.948

2.  Profile of the Nasopharyngeal Microbiota Affecting the Clinical Course in COVID-19 Patients.

Authors:  Ornella la Fortune Tchoupou Saha; Grégory Dubourg; Abdourahamane Yacouba; Vincent Bossi; Didier Raoult; Jean-Christophe Lagier
Journal:  Front Microbiol       Date:  2022-05-17       Impact factor: 6.064

3.  Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn's Disease.

Authors:  Davide Giuseppe Ribaldone; Gian Paolo Caviglia; Amina Abdulle; Rinaldo Pellicano; Maria Chiara Ditto; Mario Morino; Enrico Fusaro; Giorgio Maria Saracco; Elisabetta Bugianesi; Marco Astegiano
Journal:  J Clin Med       Date:  2019-10-09       Impact factor: 4.241

4.  Proof of Concept of Culturomics Use of Time of Care.

Authors:  Sabrina Naud; Saber Khelaifia; Maxime Descartes Mbogning Fonkou; Niokhor Dione; Jean-Christophe Lagier; Didier Raoult
Journal:  Front Cell Infect Microbiol       Date:  2020-11-23       Impact factor: 5.293

5.  Incidence and Outcome of Coinfections with SARS-CoV-2 and Rhinovirus.

Authors:  Elisabeth Le Glass; Van Thuan Hoang; Céline Boschi; Laetitia Ninove; Christine Zandotti; Aurélie Boutin; Valérie Bremond; Grégory Dubourg; Stéphane Ranque; Jean-Christophe Lagier; Matthieu Million; Pierre-Edouard Fournier; Michel Drancourt; Philippe Gautret; Philippe Colson
Journal:  Viruses       Date:  2021-12-16       Impact factor: 5.048

6.  The First Case of Clostridium saudiense Bacteremia in a Patient with Hepatocellular Carcinoma.

Authors:  Eungjun Yoon; Tae Yeul Kim; Won Young Heo; Onkyun Kang; Hui-Jin Yu; Joon Hyeok Lee; Jae-Hoon Ko; Nam Yong Lee; Hee Jae Huh
Journal:  Ann Lab Med       Date:  2022-07-01       Impact factor: 4.941

7.  "Bacterial Consortium": A Potential Evolution of Fecal Microbiota Transplantation for the Treatment of Clostridioides difficile Infection.

Authors:  Gianluca Quaranta; Gianluca Ianiro; Flavio De Maio; Alessandra Guarnaccia; Giovanni Fancello; Chiara Agrillo; Federica Iannarelli; Stefano Bibbo; Amedeo Amedei; Maurizio Sanguinetti; Giovanni Cammarota; Luca Masucci
Journal:  Biomed Res Int       Date:  2022-08-08       Impact factor: 3.246

8.  Application of LpxC enzyme inhibitor to inhibit some fast-growing bacteria in human gut bacterial culturomics.

Authors:  Fengyi Hou; Yuxiao Chang; Zongyu Huang; Ni Han; Lei Bin; Huimin Deng; Zhengchao Li; Zhiyuan Pan; Lei Ding; Hong Gao; Ruifu Yang; Fachao Zhi; Yujing Bi
Journal:  BMC Microbiol       Date:  2019-12-30       Impact factor: 3.605

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.